Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2006

01-02-2006 | Commentary

Choosing the right combination therapy in severe community-acquired pneumonia

Authors: Grant W Waterer, Jordi Rello

Published in: Critical Care | Issue 1/2006

Login to get access

Abstract

Recent studies have suggested that combination antibiotic therapy is preferable to monotherapy for severe community-acquired pneumonia (CAP). In this issue Mortensen and colleagues present retrospective data suggesting that combination therapy with a cephalosporin and a fluoroquinolone is inferior to combination therapy with a cephalosporin and a macrolide. Several mechanisms exist by which quinolones could be inferior to macrolides in combination therapy, so if these findings are confirmed by other groups they have significant implications for physicians treating patients with severe CAP.
Literature
1.
Mufson MA, Stanek RJ: Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 1999, 107: 34S-43S. 10.1016/S0002-9343(99)00098-4CrossRefPubMed
2.
Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161: 1837-1842. 10.1001/archinte.161.15.1837CrossRefPubMed
3.
Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36: 389-395. 10.1086/367541CrossRefPubMed
4.
Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al.: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170: 440-444. 10.1164/rccm.200311-1578OCCrossRefPubMed
5.
Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, et al.: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11: 589-593.PubMed
6.
Dudas V, Hopefl A, Jacobs R, Guglielmo BJ: Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000, 34: 446-452. 10.1345/aph.19174CrossRefPubMed
7.
Brown RB, Iannini P, Gross P, Kunkel M: Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003, 123: 1503-1511. 10.1378/chest.123.5.1503CrossRefPubMed
8.
Houck PM, MacLehose RF, Niederman MS, Lowery JK: Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1995, and 1997. Chest 2001, 119: 1420-1426. 10.1378/chest.119.5.1420CrossRefPubMed
9.
Garcia Vazquez E, Mensa J, Martinez JA, Marcos MA, Puig J, Ortega M, Torres A: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005, 24: 190-195. 10.1007/s10096-005-1295-9CrossRefPubMed
10.
Mortensen EM, Restrepo MI, Anzueto A, Pugh J: The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2006, 10: R8. 10.1186/cc3934PubMedCentralCrossRef
11.
Lagrou K, Peetermans WE, Jorissen M, Verhaegen J, Van Damme J, Van Eldere J: Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 2000, 46: 717-723. 10.1093/jac/46.5.717CrossRefPubMed
12.
Parnham MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18: 125-131. 10.1097/01.qco.0000160901.71813.feCrossRefPubMed
13.
Sabria M, Pedro-Botet ML, Gomez J, Roig J, Vilaseca B, Sopena N, Banos V: Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005, 128: 1401-1405. 10.1378/chest.128.3.1401CrossRefPubMed
14.
Williams AC, Galley HF, Watt AM, Webster NR: Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 2005, 56: 502-506. 10.1093/jac/dki251CrossRefPubMed
15.
Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, Galovic R, Glojnaric I, Manojlovic Z, Munic V, et al.: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002, 450: 277-289. 10.1016/S0014-2999(02)02042-3CrossRefPubMed
16.
Shinkay M, Park CS, Rubin BK: Immunomodulatory effects of macrolide antibiotics. Clin Pulm Med 2005, 12: 341-348. 10.1097/01.cpm.0000187294.53696.c0CrossRef
17.
Dalhoff A, Shalit I: Immunomodulatory effects of quinolones. Lancet Infect Dis 2003, 3: 359-371. 10.1016/S1473-3099(03)00658-3CrossRefPubMed
18.
Rello J, Diaz E, Bodi M, Catalan M, Alvarez B: Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2003, 28: 1030-1035.CrossRef
19.
Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized patients with pneumonia. Arch Intern Med 1999, 159: 2562-2572. 10.1001/archinte.159.21.2562CrossRefPubMed
20.
Bodi M, Rodriguez A, Sole-Violan J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, et al.: Antibiotic prescribing for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America Guidelines on survival. Clin Infect Dis 2005, 41: 1709-1716. 10.1086/498119CrossRefPubMed
Metadata
Title
Choosing the right combination therapy in severe community-acquired pneumonia
Authors
Grant W Waterer
Jordi Rello
Publication date
01-02-2006
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3976

Other articles of this Issue 1/2006

Critical Care 1/2006 Go to the issue

Review

Clinical review: A systematic review of corticosteroid use in infections

Commentary

Practical aspects of federalizing disaster response

Commentary

The Molecular Adsorbent Recirculating System (MARS®) in the intensive care unit: a rescue therapy for patients with hepatic failure

Research

Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury

Research

A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study

Research

Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study